Articles tagged with Sars Cov 2
Researchers have found that experimental vaccines, including a protein-based vaccine candidate with an adjuvant, provide superior protection against lung disease and higher levels of neutralizing antibodies compared to mRNA vaccines. The results inform the optimization and development of COVID-19 vaccines for young infant populations.
Researchers discovered a novel interaction between the SARS-CoV-2 Spike protein and human Estrogen Receptor Alpha, which may contribute to severe coagulopathy in COVID-19 patients. The study suggests that modulating ER signaling could mitigate rare vaccine side effects.
A new serological test, PepSeq, allows scientists to quickly test antibody binding against hundreds of thousands of protein targets, helping prepare for and respond to pandemics. The technology identifies specific antibodies that provide protection against infection, holding promise for developing effective vaccines and treatments.
A global Phase 2/3 clinical trial found that vaccination with SCB-2019 reduced the risk of transmitting SARS-CoV-2 infection to household members. The study showed a significant reduction in symptomatic cases among vaccinated household contacts and indicated that vaccines can play an important role in controlling future outbreaks.
Researchers found that antibodies against one of the two main domains of the SARS-CoV-2 viral entry machinery elicit a broad antibody response against many variants. This suggests strategies for clinical development of variant-resistant vaccines.
A Brazilian team developed an electrochemical immunosensor to detect SARS-CoV-2 antibodies, achieving 88.7% sensitivity and 100% specificity in just five minutes. The device can be adapted for other diseases and has potential for monitoring seroconversion and seroprevalence.
A Johns Hopkins Medicine study found that pregnant women taking Paxlovid had a reduced risk of severe COVID-19. The research, published in JAMA Network Open, included 47 participants who received Paxlovid therapy and monitored for outcomes and complications.
A study of over 1,000 healthcare workers found that medical masks may be as effective as N95 respirators in preventing COVID-19 infection. However, the results varied across countries and were influenced by factors such as vaccine use and variant circulating during the pandemic.
A new microfluidic multiplexed chip uses CRISPR technology to detect SARS-CoV-2 and monitor antibiotic levels, offering a rapid and sensitive solution for managing COVID-19 patients. The test omits nucleic acid amplification and can be easily adapted to new virus mutations.
A recent study found that the Omicron sub-lineage BQ.1.1 is resistant to all approved antibody therapies, posing a risk to high-risk patients. The researchers emphasize the importance of developing new antibody therapies specifically targeted at currently circulating and future viral variants.
Researchers have identified a tailor-made pocket feature in the spike glycoproteins of deadly coronaviruses, including SARS-CoV-2, MERS, and Omicron. This finding could lead to the development of a pan-coronavirus treatment that exploits this pocket feature to stop virus infectivity.
Researchers found an imbalance in an important immune system signaling pathway associated with severe COVID-19. They detected dysregulation of the immune system mediated by ATP, leading to a pro-inflammatory state and potentially fatal systemic inflammation.
A team from UNIGE has revealed the existence of a hidden 'pocket' on the surface of the non-structural protein Nsp1, which could be used to develop new treatments against Covid-19. This discovery paves the way for innovative therapies targeting the Nsp1 protein and its potential application against other coronaviruses.
Researchers identified four partially hidden binding pockets on the SARS-CoV-2 virus's Nsp1 protein that could be targeted with drugs. These pockets are found to halt virus replication and prevent immune system shut-down, providing a promising lead for future coronavirus treatments.
Researchers from UCSF and the San Francisco VA Health Care System found that veterans with PTSD had an 8% increased risk of death and a 9% increased risk of hospitalization compared to those without psychiatric diagnoses. Patients with psychosis had a 58% increased risk of death and a 66% increased risk of hospitalization.
A systematic review of 36 studies found that influenza vaccination reduced the risk of SARS-CoV-2 infection by 20% and poor outcomes like ICU admission and death by 17-31%. The findings suggest that routine influenza vaccination could offer non-specific immunity against COVID-19 symptoms.
A new study published in PLOS Medicine found that COVID-19 vaccination provides significant protection against reinfection, with varying levels of effectiveness (60-94%) across different variants. The study analyzed data from over 200,000 people in Denmark and showed that vaccination offered up to 71% protection during the Alpha period...
Three circulating omicron subvariants have shown improved resistance to vaccine- and infection-generated neutralizing antibodies. BQ.1 and BQ.1.1 are dominating US infections, while BA.2.75.2 is the best at evading neutralizing antibodies.
A comprehensive database, CoviRx, has been developed to repurpose drugs against mutated SARS-CoV-2 viruses. The platform allows scientists to narrow their search from 7,817 potential candidates to a 'top 200', with 12 tested and showing promise for further investigation.
A large study found that mRNA vaccines increased myocarditis risk in younger males, especially after the second dose. Absolute rates were low, with higher observed rates compared to expected rates.
Researchers have identified genetic variants associated with natural resistance to SARS-CoV-2, including a gene linked to mucin production. These findings may help develop vaccines and treatments for viral diseases by understanding the mechanisms underlying immune responses.
Researchers found reduced levels of D-amino acids in patients with severe COVID-19 and IAV infection, suggesting they could be used as biomarkers. Supplementation with D-alanine improved survival rates and clinical outcomes in mouse models of both infections.
A new potential biomarker for severe COVID-19 has been identified by researchers at Karolinska Institutet in Sweden. Elevated levels of the cytokine IL-26 are linked to increased inflammation and tissue damage in patients with acute COVID-19.
Parental COVID-19 vaccination was associated with lower risk of hospitalization in children under 5, supporting widespread vaccination recommendations for young children. The study's results reinforce the importance of parental immunization during high-risk periods.
Researchers at Cambridge University have successfully created artificial enzymes, known as XNAzymes, that can target and destroy the genetic code of SARS-CoV-2, a promising approach to develop new antiviral drugs. The engineered enzymes are highly specific and can be programmed to attack mutated RNAs involved in cancer or other diseases.
A recent study from Linköping University found that COVID-19 reactivated several latent viruses, including the Epstein-Barr virus, in people with chronic fatigue syndrome (ME/CFS). The study suggests that these reactivated viruses may contribute to the disease's symptoms and could potentially be used as a diagnostic tool.
A cross-sectional study found that at least one post-COVID-19 symptom occurred in 59.7% of hospitalized patients and 67.5% of non-hospitalized patients two years after infection. The study suggests that small differences in symptoms at the onset of COVID-19 existed between hospitalization status.
Researchers have developed a new nasal vaccine that induces potent lung immunity and protects against SARS-CoV-2 infection in mice. The vaccine approach, which targets the nose, airways, and lungs, has shown promising results in preventing COVID-19 infection.
A new web-based tool called Taxonium is helping scientists track the evolution of SARS-CoV-2 and other viruses by analyzing massive genetic datasets. The analysis reveals that COVID-19 variants worldwide are repeatedly evolving the same mutations, suggesting a convergent evolutionary process.
Researchers identified biomarkers that predict severe Covid-19 cases with neurological symptoms, offering potential targets for drug development to prevent consequential damage. They also found a link between impaired blood-brain barrier and excessive immune response.
Researchers found that a new drug inhibiting GRP78 effectively reduces SARS-CoV-2 replication in human lung cells. The drug also shows potential in treating certain types of cancer by suppressing mutant KRAS proteins.
A study of over 111,000 veterans found that prescription of anti-SARS-CoV-2 pharmacotherapies was underused, particularly among those with risk factors for severe COVID-19 and minority groups. Veterans with limited outpatient access to these treatments were also less likely to receive them.
A study analyzing seroprevalence data found that global COVID-19 infection rates are likely higher than reported, with 59.2% of the population seropositive as of September 2021. The study suggests that two-thirds of the global population may have antibodies from vaccination or infection.
Researchers found two Korean native plants' saponins inhibit SARS-CoV-2 entry into cells by blocking membrane fusion. These compounds show promise in treating COVID-19, especially for asymptomatic cases.
A new study published in PLOS Medicine found significant long-term morbidity in children, adolescents, and adults after COVID-19 infection. Children and adolescents are at risk of post-COVID-19 syndrome, with rates of malaise, cough, and headache increased compared to controls.
A new study found that maintaining universal masking policies in schools significantly reduced COVID-19 cases among students and staff. The study showed that lifting masking requirements led to a substantial increase in cases, highlighting the importance of universal masking in reducing transmission.
Research shows COVID-19 can cause long-term changes to brain function through inflammation, affecting mood, concentration, and cognitive abilities in both young and old patients. Millions are potentially affected by this condition, also known as Long COVID.
A study by Children's Hospital of Philadelphia researchers found that COVID-19 vaccination results in higher antibody concentrations compared to natural infection, providing robust protection for mothers during pregnancy. The study also suggests optimal vaccine timing can maximize the transfer of antibodies to babies.
Researchers found that SARS-CoV-2 increases methylation of host cell RNA, which can help the virus evade the immune system. This discovery provides insights into how different variants escape immunity and offers potential avenues for novel COVID-19 treatments.
A new study confirms that COVID-19 deaths among children and young people are rare, with most fatalities occurring in those with severe neurodisability or compromised immune systems. The analysis of detailed data showed that half of COVID-19 deaths occurred within 30 days of infection.
Researchers found significant immunological differences mediating sex differences in COVID-19 responses. Infected females had higher rates of symptoms but lower viral loads, with stronger immune response gene expression and molecular signatures.
Researchers identified how SARS-CoV-2's Nsp6 protein damages heart cells, hijacking their metabolism to cause damage. A drug, 2-deoxy-D-glucose, reduced this damage by blocking sugar metabolism, offering a potential treatment for long-term COVID-19 complications.
Researchers used human brain organoids to show how SARS-CoV-2 infects and destroys synapses in cortical neurons. Sofosbuvir effectively inhibited viral replication and rescued impaired neurons, suggesting a potential treatment for Long COVID.
A study analyzing health records of veterans with SARS-CoV-2 infection and long COVID symptoms reveals the challenges of diagnosing and managing this condition. The analysis highlights complexities in clinical diagnosis and patient care.
Researchers found that COVID-19 challenge trial participants are motivated by a desire to help others, not financial gain. The study suggests that volunteers have a thorough understanding of the risks involved and are driven by altruistic intentions.
A comprehensive review and meta-analysis found that young adults under 40 have a slightly elevated risk for myocarditis or pericarditis after mRNA COVID-19 vaccination. The analysis analyzed data from over 58 million participants and explored the relationship between COVID-19 vaccine and these rare but dangerous adverse reactions.
A new study led by Duke-NUS Medical School scientists found that inactivated SARS-CoV-2 vaccines elicit a broad immune response against different proteins on the virus, while mRNA vaccines stimulate a single spike protein response. This broader T-cell response may be beneficial in preventing severe COVID-19 disease.
Recent scientific studies have shed light on the effects of exposure to earlier SARS-CoV-2 forms on immune response to Omicron variants. Researchers identified a pan-variant antibody with ultra-potent neutralizing potency, which may help reduce treatment resistance.
New research finds that believing COVID-19 is a hoax can lead to increased belief in conspiracy theories and even suspect the 2020 presidential election was stolen from Donald Trump. The study proposes the 'gateway conspiracy' hypothesis, suggesting that one conspiracy theory triggers distrust in institutions.
Researchers at Brigham and Women's Hospital developed a novel bioink capable of constructing functional and mechanically strong blood vessels. The bioink enables bioprinting of conduits with key physiological characteristics similar to native vessels, potentially serving as vascular models for grafts in surgeries and disease studies.
Researchers at Massachusetts General Hospital analyzed data from March 2020 to June 2022 to assess the severity of SARS-CoV-2 Omicron BA.2 subvariant compared to earlier variants. The study found that BA.2 was associated with lower mortality rates and reduced need for hospitalizations, invasive ventilation, and intensive care admissions.
A new anti-virus has been discovered in a medical lecture. The lectin, known as H84T-BanLec, is highly effective against many different types of coronaviruses, including those causing COVID-19 and MERS-CoV. Its unique mechanism makes it difficult for viruses to develop resistance, making it a potential 'pan-coronavirus' antiviral drug ...
Researchers have developed an intranasal COVID-19 vaccine that works against the original virus and two variants, including omicron, in hamsters. The vaccine stimulates a strong immune response both systemically and in the respiratory tract.
Amino acid GABA shows promise in reducing disease severity, viral load and death rates in SARS-CoV-2-infected mice. GABA administration inhibits inflammatory actions of immune cells, potentially providing a generalizable therapy to treat COVID-19 and future novel coronaviruses.
A new study suggests that niclosamide, an anthelmintic drug, shows promise in combating exaggerated inflammation associated with severe COVID-19. The drug's anti-inflammatory effects are attributed to its inhibition of the inflammasome mechanism, a protein complex present in defense cells.
A recent literature review found that vaccination against SARS-CoV-2 can effectively prevent adverse conditions such as stillbirth and infant death. Pregnant women with COVID-19 have an increased risk for stillbirth compared to uninfected women, and those who vaccinate can more effectively prevent these events.
A study found that 60% of healthcare workers tested positive for COVID with antigen tests after five days and 50% were positive after seven days. Antigen tests are a better proxy for indicating infectiousness than PCR tests.
A team of scientists has identified over 200 direct protein-protein contacts between the SARS-CoV-2 virus and human cells, shedding light on the mechanisms underlying severe COVID-19. The study reveals chains of connections between viral proteins and infection-relevant human genes, with implications for disease severity and treatment.
Researchers used excess mortality data to calculate a significantly lower R0 value of 1.34 for SARS-CoV-2 infections in March 2020, contrary to earlier estimates which ranged from 1.95 to 6.49.
A study of 7,800 children under 5 years old found comparable side effects between Pfizer-BioNTech and non-COVID-19 vaccines. The results could inform vaccination recommendations for this age group.